13th Global Drug Delivery & Formulation Summit (DDF 2022)

Focusing on solutions to some of the biggest challenges in drug delivery and formulation, the 13th Global Drug Delivery and Formulation Summit (DDF, Berlin, 27 - 29 June 2022) will cover formulation design, formulation for deliverability, controlled release and delivery device technologies. Our expert will present on innovative solutions to meet the challenges of biopharmaceutical development and delivery. 

13^th DDF CONFERENCE PRESENTATION:

Inhaled Delivery of Biologics: Why it’s a Good Solution

Biologics present numerous challenges in their successful manufacture, formulation, and delivery to the patient. Respiratory delivery of biologics presents opportunities for both targeted delivery of these drug substances as well as alternative systemic delivery routes to the traditional needle-based administration options currently used. This presentation will discuss the available technologies and approaches being used to build effective products, as well as a discussion of the regulatory considerations when taking this complex combination of new drug modalities and delivery routes through to market

REQUEST PRESENTATION 
We would be delighted to send the presentation slides after the conference.

Our scientists provide development support for a wide range of pharmaceutical dosage forms with specialist expertise in OINDP development with integrated formulation and testing services for both small molecules and biologics. We provide critical performance and quality testing such as laser particle sizing, aerodynamic particle size distribution (APSD) by impaction (ACI, NGI) and spray pattern/plume geometry. Intertek’s integrated formulation development and analytical teams carry out early-stage pre-formulation support, solubility screening, drug-excipient compatibility, stability testing, and device selection support. For inhaled biologic development, comprehensive protein characterisation services supported by forced degradation and stability monitoring for the protein’s structure and bioactivity throughout formulation and storage can also be provided. Interaction with the device and closure systems are evaluated through comprehensive extractable and leachable testing and toxicological assessments.

With 30 years of experience in supporting our clients’ inhaled and nasal product developments, we deliver world-class support to help you meet the challenges of your demanding development programs. The Intertek Melbourn Laboratory is inspected and approved by the UK Medicines & Healthcare Products Regulatory Agency (MHRA) for GMP compliance. The Laboratory has also been inspected by the US Food and Drug Administration (FDA) against GMP as part of clients’ pre-approval inspections.

RESOURCES:
ARTICLE: Intranasal Delivery of Biologics and Vaccines
ARTICLE: In Vitro Bioequivalence for Pulmonary and Nasal Delivery
BROCHURE: Intertek Inhaled Product Development Brochure 
WEBINAR: Formulation and Manufacturing Approaches for Nasal Drug Products